Fujifilm Diosynth to create biocampus in the UK

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/champc)
(Image: Getty/champc)

Related tags: Fujifilm diosynth biotechnologies, Fujifilm, facility

Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.

Located in Billingham, UK, the research center, known as BioCampus, will include a 42,000-square-foot office space, which is expected to house approximately 250 of the company’s existing employees, with an additional 50 people to be hired.

The site will have the potential to be expanded in the future with additional R&D laboratories or manufacturing facilities.

The project will see Fujifilm Diosynth Biotechnologies invest up to £14.5m ($17.11m), utilizing funding by the Tees Valley Mayor and Combined Authority, as well as from the UK government’s Local Growth Fund.

By building the new facility, Fujifilm Diosynth expects to meet the growing demand for its portfolio of partner programs, including development and manufacturing services of biologics, vaccines and gene therapies, the company stated.

Paul Found, the company’s chief operating officer, stated that the BioCampus will enable Fujifilm Diosynth to significantly enhance the quality of the working environment for its employees.

Construction of the BioCampus is expected to be completed by March 2021.

Related news

Show more

Related products

show more

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us

Products

View more

Webinars